Pharma Focus Asia

Clene Nanomedicine, Inc. Announces Selection of CNM-Au8 for the Harvard Led HEALEY ALS Platform Trial, a Clinical Trial for Amyotrophic Lateral Sclerosis

Thursday, September 19, 2019

Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, announced today that the Sean M. Healey & AMG Center for ALS at Mass General has selected CNM-Au8 for inclusion in the first ever Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS).

The Healey Center issued a call earlier this year for the best therapeutic candidates to apply for entry into the HEALEY ALS Platform Trial. They received responses from nearly 30 applicants across ten countries. Members from the Healey Center Science Advisory Committee, a group of renowned ALS scientists, chose the top five therapeutic candidates, including Clene's lead clinical asset, CNM-Au8. The selection of CNM-Au8 into the Healey ALS Platform Trial includes substantial financial support and provides access to over 50 expert ALS clinical trial sites across the United States.

"Our goal," said Merit Cudkowicz, MD, MSc, Director of the Healey Center, "is to lower the barriers for our pharma and academic colleagues to bring their exciting therapies for ALS forward to clinical trials. We are determined to accelerate therapy development for ALS."

Important preclinical work supporting the effort with CNM-Au8 was performed in the laboratory of Nicholas J. Maragakis, Director of the ALS Center for Cell Therapy and Regeneration Research at Johns Hopkins, using human induced pluripotent stem cells from ALS patients. Dr. Maragakis is Chair of Clene's Scientific Advisory Board for ALS.

Dr. Jonathan Glass, Professor of Neurology and Pathology at Emory University School of Medicine, as well as Director of the Emory ALS Center, remarked, "CNM-Au8 is quite an interesting compound that is ready for testing in ALS clinical trials.  Its inclusion in the Platform Trial initiative is an excellent way to move forward for the development of CNM-Au8 as a potential therapeutic for ALS."

"We are very pleased Clene's CNM-Au8 has been selected for participation in the Healey ALS Platform Trial. We believe the unique mechanism of CNM-Au8 represents a promising new approach for the treatment of neurodegenerative diseases, including ALS, with the potential for meaningful impact for the community of people diagnosed with this devastating and debilitating disease," said Rob Etherington, President and CEO of Clene. "We are continuing the development of CNM-Au8 in several clinical studies set to launch later this year."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024